OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Choudhri on the Impact of Artificial Intelligence in Cancer Care

April 4th 2022

Ajay Choudhri, MD, discusses the impact of developments in artificial intelligence in cancer care.

Dr. George on Efforts to Address Unmet Needs in HER2-Low Breast Cancer

April 1st 2022

Mridula George, MD, discusses efforts to address unmet needs in HER2-low breast cancer.

Dr. Dietrich on the Current Treatment Landscape of MCL

April 1st 2022

Martin Dietrich, MD, PhD, discusses the current treatment landscape of mantle cell lymphoma.

Dr. Verstovsek on the Efficacy of Momelotinib in Myelofibrosis

April 1st 2022

Srdan Verstovsek, MD, PhD, discusses the efficacy of momelotinib in myelofibrosis.

Dr. Leslie on the FDA Approval of Axicabtagene Ciloleucel for Second-Line Relapsed/Refractory LBCL

April 1st 2022

Lori A. Leslie, MD, discusses the FDA approval of axicabtagene ciloleucel for second-line relapsed/refractory large B-cell lymphoma.

Dr. Marshall on Utilizing Precision Medicine in Bile Duct Cancer

March 31st 2022

John L. Marshall, MD, discusses potential next steps with research in bile duct cancer.

Dr. Mesa on the Rationale for the MOMENTUM Trial in Myelofibrosis

March 31st 2022

Ruben A. Mesa, MD, discusses the rationale for the phase 3 MOMENTUM study in myelofibrosis.

Dr. Osarogiagbon on the Effects of the COVID-19 Pandemic on Lung Cancer Screening

March 31st 2022

Raymond U. Osarogiagbon, MD, FACP, discusses the long-term effects of the COVID-19 pandemic on lung cancer screenings.

Dr. Ramalingam on the Clinical Examination of Patritumab Deruxtecan in NSCLC

March 30th 2022

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the exploration of patritumab deruxtecan in non–small cell lung cancer.

Dr. Stein on Key Highlights of the AUGMENT-101 Trial in Leukemias

March 30th 2022

Eytan M. Stein, MD, discusses the key highlights of the phase 1/2 AUGMENT-101 trial in leukemias.

Dr. Sallman on the Examination of Magrolimab in AML

March 30th 2022

David Sallman, MD, discusses the examination of magrolimab in acute myeloid leukemia.

Dr. Cutler on the Examination of Itolizumab in aGVHD

March 30th 2022

Corey S. Cutler, MD, MPH, FRCPC, discusses the exploration of itolizumab in acute graft-versus-host disease.

Dr. Ramalingam on Investigating Osimertinib Combination Approaches in NSCLC

March 30th 2022

Suresh S. Ramalingam, MD, FACP, FASCO, discusses ongoing trials investigating osimertinib combination approaches in non-small cell lung cancer.

Dr. Mok on the Results of the U31402-A-U102 Trial in NSCLC

March 30th 2022

Tony SK Mok, MD, discusses the rationale for the phase 1 U31402-A-U102 trial in metastatic or unresectable non–small cell lung cancer.

Dr. Weksler on Addressing Disparities in Lung Cancer Care Delivery

March 26th 2022

Benny Weksler, MD, MBA, FACS, FACCP, discusses efforts being made at Allegheny Health Network Cancer Institute to address disparities in the delivery of care and its impact on the screening and treatment of lung cancer.

Dr. Redjal on Technological Advances in Neurosurgical Oncology

March 26th 2022

Navid Redjal, MD, FAANS, discusses technological advances that have impacted neurosurgical oncology.

Dr. Bechara on Minimally Invasive Bronchoscopic Approaches in Lung Cancer

March 26th 2022

Rabih I. Bechara, MD, FCCP, discusses how minimally invasive bronchoscopic approaches are utilized in lung cancer.

Dr. Koreth on Key Objectives of the EQUATOR Trial in aGVHD

March 24th 2022

John Koreth, MBBS, DPhil, discusses the key objectives of the phase 3 EQUATOR trial in acute graft-versus-host disease.

Dr. Kadia on the Utilization of Uproleselan with Chemotherapy in R/R AML

March 24th 2022

Tapan M. Kadia, MD, discusses the utilization of uproleselan with chemotherapy in relapsed/refractory acute myeloid leukemia.

Dr. Becker on the Rationale for Investigating Uproleselan in Combination with Chemotherapy in AML

March 24th 2022

Pamela S. Becker, MD, PhD, discusses the rationale for investigating uproleselan in combination with chemotherapy in relapsed/refractory acute myeloid leukemia.